Overview

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Status:
Not yet recruiting

Trial end date:
2023-06-10

Target enrollment:

Participant gender:

Summary

This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy in advanced solid tumours that have progressed following SoC treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Redx Pharma Plc

Treatments:

Denosumab